Goldman Scarlato & Karon, P.C. Announces Investigation of Clinical Data, Inc.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Goldman Scarlato & Karon, P.C. (“GSK”) is investigating potential legal claims against the Board of Directors of Clinical Data, Inc. (“Clinical Data”) (NASDAQ: CLDA) relating to the proposed buyout of Clinical Data by Forest Laboratories, Inc. The definitive acquisition agreement, announced on February 22, 2011, involves an all-cash, going-private transaction valued at approximately $1.2 billion, or $30.00 per share. The acquisition price reflects an 11.5 percent discount to Clinical Data’s February 18, 2011 closing price of $33.90.